Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation.
allogeneic hematopoietic stem cell transplantations
hyperthyroidism
hypothyroidism
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
27
06
2020
accepted:
20
07
2020
pubmed:
28
7
2020
medline:
24
6
2021
entrez:
27
7
2020
Statut:
ppublish
Résumé
Thyroid dysfunction (TD) is one of the major endocrinopathies shown after allogeneic hematopoietic stem cell transplantation over the long term. The incidence and the risk factors for TD have varied widely. Two hundred and fifty-nine patients with pre-transplant normal thyroid function tests who survived at least 1 year after allo-HSCT between 2006-2016 were included in the study. Sixty-four patients (25%) developed TD at median of 34 months (range, 1-112 months). Hypothyroidism was detected in 32 patients (12%): 5 patients had primary hypothyroidism, and subclinical hypothyroidism occurred in 27 patients. 18 patients (7%) were diagnosed with hyperthyroidism: 2 patients (0.07%) were treated for primary hyperthyroidism, and 16 patients (6%) were followed for subclinical hyperthyroidism. Euthyroid sick syndrome occurred in 14 cases. None of the patients with thyroid dysfunction developed secondary thyroid malignancy. Receiving high-dose TBI (P = .001) was found to be significant risk for hypothyroidism; older age than median (P = .01) and pre-transplant active disease (P < .0001) were related to hyperthyroidism. Thyroid dysfunction, mostly hypothyroidism, is a long-term complication after allo-HSCT in 25% of patients. Older age, pre-transplant active disease, and receiving TBI are among the risk factors. Sustained long-term monitoring of thyroid function test should be considered post allo-HSCT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14049Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Atilla E, Atilla PA, Toprak SK, Demirer T. A review of late complications of allogeneic hematopoietic stem cell transplantations. Clin Transplant. 2017;31(10):e13062.
Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(3):348-371.
Brennan BM, Shalet SM. Endocrine late effects after bone marrow transplant. Br J Haematol. 2002;118:58-66.
Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017;102:614-625.
Cornillon J, Vantyghem MC, Couturier MA, et al. Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on dyslipidemia and thyroid disorders. Pathologie Biologie. 2013;61(4):168-170.
Ito R, Inamoto Y, Inoue Y, et al. Characterization of late acute and chronic graft-versus-host disease according to the 2014 national institutes of health consensus criteria in Japanese patients. Biol Blood Marrow Transplant. 2019;25(2):293-300.
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid assoication task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751.
Ross DS, Burch HB, Cooper DS, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practives for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplanttion, Center for International Blood and Marrow Tranplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant. 2006;37(3):249-261.
Toubert ME, Socie G, Gluckman E, et al. Short- and long-term follow-up of thyroid dysfunction after allogeneic bone marrow transplantation without the use of preparative total body irradiation. Br J Haematol. 1997;98(2):453-457.
Farhadfar N, Stan MN, Shah P, et al. Thyroid dysfunction in adult hematopoietic cell transplant surviviors:risks and outcomes. Bone Marrow Transplant. 2018;53(8):977-982.
Paviglianiti A. Endocrine and metabolic disorders after hematopoietic stem cell transplantation. Turk J Haematol. 2020;37(2):111-115.
Al-Fiar FZ, Colwill R, Lipton JH, Fyles G, Spaner D, Messner H. Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants. Bone Marrow Tranplant. 1997;19(10):1019-1022.
Martin PJ, Inamoto Y, Carpenter PA, Lee SJ, Flowers ME. Treatment of chronic graft-versus host disease: past, present and future. Korean J Hematol. 2011;46(3):153-163.
Vantyghem MC, Marcelli-Tourvielle S, Pattou F, Noël C. Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation. Ann Endocrinol. 2007;68:21-27.
Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215-233.
Littley MD, Shalet SM, Morgenstern GR, Deakin DP. Endocrine and reproductive dysfunction following fractionated total body irradiation in adults. Q J Med. 1991;78(287):265-274.
Cohen A, Bekassy AN, Gaiero A, et al. EBMT Paediatric and Late Effects Working Parties. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Tranplant. 2008;41(Supp 2):S43-S48.
Savani BN, Koklanaris EK, Le Q, Shenoy A, Goodman S, Barrett AJ. Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2009;15:377-381.
Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:693-702.
Tatevossian R, Blair JC, Plowman PN, Savage MO, Shankar AG. Thyrotoxicosis after matched unrelated bone marrow transplantation. J Pediatr Hematol Oncol. 2004;26:529-531.
Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant. 1998;22:873-881.
Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood. 2002;99:768-784.
McDermott MT. Hyperthyroidism. Ann Intern Med. 2020;172(7):ITC49-ITC64.
Cohen A, Rovelli A, Df M, et al. Risk for secondary thyroid carcinoma after hematopoeitc stem-cell transplantation: an EBMT late effect working party study. J Clin Oncol. 2007;25(17):2449-2454.